The Company was founded by experienced biotech industry executives and pharmaceutical researchers who successfully led a new drug project from discovery through multiple clinical studies and subsequent acquisition by the global pharmaceutical company GlaxoSmithKline (GSK).
At Resolvex, we are focused on the discovery, development, and commercialization of novel stilbenoid phytoalexin-based therapeutics for chronic diseases. Phytoalexins are unique compounds that are synthesized in plants in response (an evolutionarily conserved biological process named hormesis) to biotic and abiotic stresses to protect plants from diseases and infections. It is known that numerous plant-based hormetic agents play a central role in affecting healthy aging, slowing the onset and progression of numerous neurodegenerative and other age-related diseases, and reducing risks and damage due to heart attacks, stroke, and other serious conditions of public health and medical importance (through a process named xeno hormesis). Our goal is to harness nature’s phytoalexins (hormetic compounds) into specifically targeted therapeutics for major unmet medical needs.